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Purpose: To explore the published evidence on the link between treatment satisfaction and 
patients’ compliance, adherence, and/or persistence.
Methods: Articles published from January 2005 to November 2010 assessing compliance, 
adherence, or persistence and treatment satisfaction were identified through literature searches 
in Medline, Embase, and PsycInfo. Abstracts were reviewed by two independent researchers 
who selected articles for inclusion. The main attributes of each study examining the link between 
satisfaction and adherence, compliance, or persistence were summarized.
Results: The database searches yielded 1278 references. Of the 281 abstracts that met the 
inclusion criteria, 20 articles were retained. In the articles, adherence and compliance were often 
used interchangeably and various methods were used to measure these concepts. All showed a 
positive association between treatment satisfaction and adherence, compliance, or persistence. 
Sixteen studies demonstrated a statistically significant link between satisfaction and compliance 
or persistence. Of these, ten demonstrated a significant link between satisfaction and compliance, 
two showed a significant link between satisfaction and persistence, and eight demonstrated a link 
between either a related aspect or a component of satisfaction (eg, treatment convenience) or 
adherence (eg, intention to persist). An equal number of studies aimed at explaining compliance 
or persistence according to treatment satisfaction (n = 8) and treatment satisfaction explained by 
compliance or persistence (n = 8). Four studies only reported correlation coefficients, with no 
hypothesis about the direction of the link. The methods used to evaluate the link were varied: two 
studies reported the link using descriptive statistics, such as percentages, and 18 used statistical 
tests, such as Spearman’s correlation or logistic regressions.
Conclusion: This review identified few studies that evaluate the statistical association between 
satisfaction and adherence, compliance, or persistence. The available data suggested that greater 
treatment satisfaction was associated with better compliance and improved persistence, and with 
lower regimen complexity or treatment burden.
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Introduction
Adherence to medication has been recognized as a key issue in health outcomes and 
efforts to improve patients’ adherence are being made by the pharmaceutical industry, 
experts, and government bodies alike. The “Ascertaining Barriers for Compliance” 
European research project is one such initiative, whose aim is to identify and 
disseminate methods for promoting adherence. Inadequate adherence reduces the 
effectiveness of treatment, and this can lead to complications, deterioration in health, 
and ultimately death. This represents a significant burden not just for patients but also 
for the healthcare team, healthcare system, and society. These costs are both personal 
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and societal, such as those caused by complications, hospi-
talization, or absenteeism.1,2
There are a number of elements that determine a patient’s 
adherence to their treatment, including dosing   complexity 
and frequency, convenience, and satisfaction. Indeed, 
the association between treatment satisfaction and adherence 
is clinically intuitive. If a patient is dissatisfied with treat-
ment, this may negatively affect their behaviors in terms of 
quality of treatment regimen execution but also in terms of 
their involvement in treatment, their perception and attitude 
toward treatment, and intention to persist. Satisfaction with 
treatment is increasingly recognized as an important and 
sensitive measure for treatment differentiation and its mul-
tidimensionality is well documented.3–8 Indeed, this link is 
one that is often suggested in articles and research, and yet 
the evidence available for this link and how it is measured 
has not been recently reviewed.
The objective of this literature review was to identify the 
link between treatment satisfaction and adherence. A clear 
understanding of the nature of this link could be of use for 
clinical practice and future investigations.
Material and methods
Search strategy and selection criteria
Published data assessing compliance, adherence, or per-
sistence and treatment satisfaction from the past 5 years 
(from January 2005 to November 2010) was searched for in 
Medline, Embase, and PsycInfo databases. The search per-
formed used the following commands: (“compliance” OR 
“persistence” OR “adherence”) AND (“satisfaction”) AND 
(“medicines” OR “drug” OR “medication”). These searches 
were limited to abstracts on human subjects and in English. 
As there is currently no consensus regarding the definitions 
of adherence, compliance, or persistence, all three terms 
were retained in the search. Abstracts were retained for the 
following step if they included the terms, (a) satisfaction or 
dissatisfaction, (b) adherence, compliance, or persistence, 
and (c) reference to a drug or medication or if reference was 
made to mode of administration associated with adherence, 
compliance, or persistence. Abstracts meeting these criteria 
were ranked one, two, or three according to the pertinence 
of their content and results. Figure 1 illustrates the series of 
steps followed and ranking criteria used during this abstract 
Search in Medline, Embase and Psyclnfo: (Compliance OR Persistence OR Adherence) AND (Satisfaction) AND
(Medicines OR Drug OR Medication). Published from 2005 to 2010, in English, with abstracts.
1278 abstracts reviewed
281 abstracts reviewed
Selection criteria for inclusion of abstracts: abstract includes Satisfaction or Dissatisfaction, at least one of the
Adherence terms and reference to a Drug or Medication OR mode of administration associated with adherence terms.
Rank 1 criteria: Satisfaction and Adherence
in title and/or abstract, and the main focus of
the article.
Rank 3 criteria: a) Relevant terms in
background or discussion b) No real data
Rank 2 criteria: a) Satisfaction and
Adherence in abstract but not the main aim
of article b) Relevant results in the abstract
95 references
excluded
186 abstracts studied by
second reviewer
Criteria for articles to be ordered: study of link between satisfaction and an adherence term
in objectives OR results on satisfaction and adherence, compliance or satisfaction
72 articles
studied by 2
reviewers
Criteria for inclusion of articles: empirical study results on link between satisfaction and
adherence compliance or satisfaction, using statistical tests or descriptive statistics
20 articles
included
Figure 1 Steps and criteria for abstract and article selection.
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and article selection. Articles with no relevant results were 
ranked three and excluded. Rank one and two abstracts were 
reviewed in detail by another researcher and a subset of 
articles that studied the link between satisfaction and adher-
ence, compliance, or persistence, or that had results on both 
satisfaction and adherence, compliance, or persistence, were 
ordered. The articles were analyzed in depth and those that 
reported empirical results on the link between satisfaction 
and adherence using statistical tests or descriptive statistics 
were retained. The study design, patient population, study 
objectives, measurement   methods, treatment(s) studied, 
and results on the link between satisfaction and adherence, 
compliance, or persistence were reported in a table.
Results
The database searches yielded 1278 references. Abstracts that 
met the inclusion criteria were then submitted to the selection 
process (n = 281). Abstracts that were ranked one or two were 
reviewed by a second reviewer (n = 186), and 72 articles of 
those were selected for in depth analysis. Finally, 20 articles 
were identified that reported results on the link between 
satisfaction and adherence, compliance or persistence.9–28 Of 
the 20 studies included, 15 were observational studies, four 
were randomized controlled trials, and one was a nonrandom-
ized clinical trial. The most frequent diseases in which these 
studies were carried out were glaucoma, diabetes, osteopo-
rosis and schizophrenia. These studies and their results are 
presented in Table 1.
Methods used to evaluate satisfaction  
and adherence, compliance, or persistence
The studies measuring compliance or adherence used vali-
dated or study-specific questionnaires, clinician judgment, 
or refill/prescription data to measure these behaviors. Persis-
tence was measured with number of days in study, unvali-
dated questionnaires, or clinician judgment.   Satisfaction 
was measured by validated or unvalidated questionnaires or 
interviews. Satisfaction was generally measured using self-
report questionnaires, a standard and well-accepted way of 
measuring this outcome.
The terms used: adherence, compliance, 
and persistence
The articles included in this review did not provide a 
consensus on definitions of adherence, compliance, or 
  persistence. Various definitions were used for these terms, 
often interchangeably across publications. For example, 
eleven studies10,11,15,16,18,21–23,25,27,28 measured compliance, that 
is to say the quality of drug regimen execution, by asking 
questions about missing doses, forgetting doses, or skipping 
doses, or using “objective” measures such electronic system 
or pill count, but called it adherence. The multidimensional 
term of adherence was rarely measured using a questionnaire 
that measures the concept in its entirety, as defined by the 
World Health Organization.1
Methods used to evaluate links
The evaluation methods used were varied in terms of the 
tests used and their complexity. The majority of studies used 
statistical tests such as Spearman’s correlation or logistic 
regressions to evaluate the link between satisfaction and 
adherence, compliance, or persistence.10–19,21,22,24–29 Only two 
studies reported a link using descriptive statistics such as 
percentages.20,23 Even though the causal relationship between 
satisfaction and adherence, compliance, or persistence was 
not explicitly investigated in these studies, the direction of 
the relationship was studied. An equal number of studies 
aimed at reporting on compliance or persistence explained 
by treatment satisfaction18–22,24,25,27 and treatment satisfaction 
explained by compliance or persistence.9–16 Four studies only 
reported correlation coefficients, which do not specify any 
hypothesis about the direction of the link.17,23,26,28
Links identified
Of the 20 studies that examined the link between satisfac-
tion and adherence, compliance, or persistence, only a small 
number explicitly stated the study of this relationship in 
their objectives.10,19,22,25 The other studies mentioned either 
satisfaction or adherence, compliance, or persistence in their 
objectives, mostly when examining the determinants of one 
of these elements. All studies showed a positive association 
between treatment satisfaction and adherence, compliance, 
or persistence; the most satisfied patients were the most 
compliant or persistent and the least satisfied were the least 
compliant or persistent. Of the 20 studies, 16 demonstrated 
a link between satisfaction and compliance or persistence 
that was statistically significant.9–14,16–19,21,22,25–28 For the four 
studies that did not demonstrate a statistically significant link, 
one reported that significant results had been found but did 
not report what the results were,15 two did not use statistical 
tests,20,23 and one had results that did not reach statistical sig-
nificance but showed a trend of positive association between 
satisfaction and compliance.24
Of the 16 studies that demonstrated statistically sig-
nificant links, ten showed a link between satisfaction 
and compliance9,11–14,16,18,19,22,27 and two studies showed a 
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c
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r
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c
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c
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p
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c
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c
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c
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p
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c
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c
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.
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.
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.
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c
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c
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p
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c
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c
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c
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c
e
 
w
i
t
h
 
a
c
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c
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c
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e
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c
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c
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c
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c
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i
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c
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r
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b
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c
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c
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c
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p
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.
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i
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i
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c
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n
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c
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c
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c
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.
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c
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i
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c
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c
t
u
r
a
l
 
e
q
u
a
t
i
o
n
 
m
o
d
e
l
:
 
d
i
r
e
c
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c
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e
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p
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p
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b
e
t
w
e
e
n
 
s
a
t
i
s
f
a
c
t
i
o
n
 
a
n
d
 
 
a
d
h
e
r
e
n
c
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c
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p
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c
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  significant link between satisfaction and persistence.16,19 The 
multidimensional aspect of satisfaction and adherence was 
not always fully studied. The four other studies that showed 
statistically significant results were among several studies 
that demonstrated a link between either a related aspect or 
a component of satisfaction and adherence, compliance, or 
persistence. For instance, treatment convenience, effective-
ness, ease of use, acceptability, or tolerability were investi-
gated as elements of treatment satisfaction.9,21,26 Concepts 
close to compliance or adherence, such as “reluctance to use 
medications,” “never thinking about stopping,” or “barriers 
to adherence”10,17,21,25,28 were also analyzed.
Significant relationships between satisfaction and compli-
ance or persistence were found more frequently in observational 
studies than in randomized controlled trials; the majority of 
these observational studies were cross-sectional in design.
Four studies focused on the change in treatment fre-
quency or route of administration and demonstrated that less 
treatment burden entailed greater satisfaction and greater 
compliance. Two randomized controlled trials compared 
subcutaneous to inhaled treatment for diabetes; patients with 
less previous or current treatment burden had higher treat-
ment satisfaction,14 and lower adherence barriers were found 
for patients with inhaled insulin versus subcutaneous insulin 
injection.28 A nonrandomized clinical trial demonstrated 
that patients with poor compliance with previous weekly 
treatment were twice more likely to be satisfied with new 
monthly treatment for osteoporosis.13 In an observational 
study on subcutaneous versus oral treatment for iron chela-
tion therapy, greater satisfaction in the oral treatment group 
was found and “never thinking about stopping treatment” 
was associated with less burden of treatment.25
Discussion
The purpose of this review was to explore the evidence avail-
able on the link between treatment satisfaction and adher-
ence, compliance, or persistence. Even though the number 
of published studies was quite limited, the data available 
supported a positive link between treatment satisfaction and 
compliance and/or persistence. The link between satisfac-
tion and compliance is well established; greater satisfaction 
being associated with greater compliance or on the contrary, 
greater dissatisfaction being associated with poorer compli-
ance. This link was demonstrated for a large spectrum of 
diseases (eg, osteoporosis, diabetes, psychosis, glaucoma) 
and in different settings (clinical trials and observational 
studies). This link was also studied with different routes 
and   frequencies of administration; greater satisfaction or 
  compliance being associated with lower regimen   complexity 
or treatment burden. The link between satisfaction and per-
sistence was also demonstrated, albeit less frequently; greater 
satisfaction was associated with more time in the study or 
more time on medication. These results were consistent 
with theoretical models6,30 in which satisfaction with treat-
ment leads to positive behaviors. Thus, the evidence from 
16 of the 20 studies that demonstrated the statistical link 
between satisfaction and adherence, compliance, or persis-
tence supported the intuitive and theoretical link between 
these concepts. Moreover, the direction of the link was 
also examined and significant results were reported in both 
directions:   satisfaction explaining compliance/persistence 
and   compliance/persistence explaining satisfaction. This 
is evidence of the interrelated and dynamic nature of these 
concepts that certainly have some common drivers.
These results should be considered in light of the vari-
ability in definitions used for adherence, compliance, and 
persistence. Indeed, the review confirmed that there is no 
acknowledged single definition for these terms, and adher-
ence, compliance, and persistence are often used interchange-
ably across publications. The multidimensional aspects of 
satisfaction and adherence were not always fully studied. 
Moreover, there was great diversity in measurement methods 
used for satisfaction, adherence, compliance, and persistence. 
Questionnaires used across studies were different even for a 
same condition, and many of them were partially or not at all 
validated. It was noted that there is no commonly accepted 
threshold for “good” or “bad” satisfaction and “acceptable” 
or “inadequate” compliance or persistence rates, meaning 
that results are interpreted inconsistently.
Possibilities for the generalization of study results may 
be limited by the diversity in study designs, definitions, 
and measurement methods used for satisfaction, adherence, 
compliance, and persistence, as well as by the variability 
in methods used to evaluate the link in terms of tests and 
complexity.
The studies considered were reports from different 
research designs: randomized controlled trials, nonrandom-
ized clinical trials, and observational studies. Measuring 
compliance in clinical studies is important since inadequate 
compliance can reduce the effectiveness of a treatment or 
intervention. A high compliance rate in randomized con-
trolled trials ensures the quality of the study and is critical 
for the success of therapeutic outcomes evaluation. However, 
clinical trials have limitations when measuring compliance 
as these studies are conducted in specific settings, with a 
highly selected population and close patient monitoring that 
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do not reflect real life conditions. Moreover, it is unlikely that 
patients would refuse a treatment after consenting to partici-
pate and they are likely to be more motivated to use it. For 
these different reasons, rates of compliance in clinical trials 
are more likely to be overestimated compared to real life and 
the findings cannot be extrapolated. In addition, measuring 
persistence for chronic long-term therapies is limited by the 
length of the trial. If the majority of patients discontinued 
their treatment in the first year for example, the follow-up of 
patients within a 6-month study can produce incomplete or 
biased results. Similarly, cross-sectional study design limits 
the analysis of the link between treatment satisfaction and 
adherence, compliance, or persistence over time.
Another possible limitation of this review is the poten-
tial publication bias; the association may be only reported 
when it is present and simply not reported when it was not 
significant.
There is a clear need for a consensus on definitions 
and a framework for interpretation, to ensure that results of 
well-  designed studies that appropriately assess this asso-
ciation using a rigorous methodological approach can be fully 
explored. In the management of patients with chronic diseases, 
it is important to understand the determinants of patient 
satisfaction with various therapeutic alternatives as these factors 
are likely to have a great impact on compliance and persistence 
with therapy over time. In the context of clinical practice, the 
routine assessment of satisfaction with treatment and/or adher-
ence using validated patient questionnaires could help physicians 
to identify patients facing adherence or satisfaction issues and 
needing specific support. The support may take the form of fur-
ther information and discussion about medication and disease, 
change of medication, regimen, or mode of administration.
Conclusion
The review of the empirical evidence on the link between 
treatment satisfaction and adherence, compliance, and per-
sistence with medication identified few studies that evalu-
ate the statistical association between these concepts. The 
available data suggested that greater treatment satisfaction 
was associated with better compliance and improved per-
sistence. These results should be taken with caution since 
there are some limitations in terms of measurement meth-
ods, study designs, and inconsistency in definitions used for 
these concepts. Well-conducted observational longitudinal 
studies including a rigorous measurement strategy for sat-
isfaction and adherence, compliance, and persistence, and 
designed specifically to explore their relationships would be 
  worthwhile to confirm these associations.
A deeper understanding of the nature of the association 
between satisfaction and adherence, compliance, or persis-
tence, and especially evidence of a causal direction, could 
have implications in the context of clinical practice and could 
help to identify strategies to increase patient satisfaction and 
promote positive behaviors with regards to treatment. One 
of the most actionable barriers for improving compliance, 
adherence, and persistence may include improving compo-
nents of treatment satisfaction, such as treatment convenience 
or side effects.
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